

Measure #410:

Psoriasis: Clinical Response to Systemic Medications or Biologic Medications —

National Quality Strategy Domain:

Person and Caregiver Centered Experience and Outcomes

HOW DO YOU WANT TO REPORT THE MEASURE?

AAD'S DATADERM

EHR

CLAIMS

Did you/your practice document assessing psoriasis vulgaris patients (regardless of age) receiving systemic therapy using the PGA, BSA, PASI, and/or DLQI meeting specified benchmarks

- PGA (5-point OR 6-point scale) ≤ 2 (clear to mild skin disease)
- BSA $< 3\%$ (mild disease)
- PASI < 3 (no or minimal disease)
- DLQI ≤ 5 (no effect or small effect on patient's quality of life) **OR** document that the patient declined therapy change, has documented contraindications, or has not been treated with a systemic for at least six consecutive months?

YES NO

Eligible Measure:
Visit
www.aad.org/410
to learn more.

NOT ELIGIBLE

Do you plan to report through your EHR directly or through integration with AAD's DataDerm registry?

DATADERM

DIRECT EHR

Contact your EHR vendor for additional guidance on reporting.



NOT ELIGIBLE

For more information, contact the American Academy of Dermatology:
WEBSITE: aad.org

© by the American Academy of Dermatology and the American Academy of Dermatology Association.
"All Rights Reserved." Reproduction or republication is strictly prohibited without prior written permission.

The Measure is copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices) without obtaining approval from NCQA.



AMERICAN ACADEMY OF
DERMATOLOGY | ASSOCIATION